Spotlight On Retina: A Discussion
Overview
NoneGrantor Statement This continuing medical education activity is supported through an educational grant from Regeneron Pharmaceuticals, Inc. Learning Objectives
Upon completion of this educational program, attendees should be able to: - Describe the long-term outcomes of VEGF-inhibitor use and practice patterns in the management of AMD.
- Distinguish the differences in the reported long-term outcomes of each study.
- Determine how to apply this data to clinical practice and patient education regarding long-term management of wet AMD.
Accreditation
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC and Avlis International, Inc.
AMA Credit Designation Statement Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Faculty and Disclosures
DISCLOSURE POLICY
The following faculty members have the following financial relationships with commercial interests: Rishi P. Singh, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Allergan Plc; Carl Zeiss Meditec; Genentech, Inc; Optos; Regeneron Pharmaceuticals, Inc; and Shire Plc. Grant/Research Support: Alcon; Apellis Pharmaceuticals; Genentech, Inc; and Regeneron Pharmaceuticals, Inc. Lloyd Clark, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Bayer Pharmaceuticals; Genentech, Inc; Ohr Pharmaceutical, Inc.; and Santen Pharmaceutical Co. Grant/Research Support: Allergan Plc; Genentech, Inc; Ohr Pharmaceutical, Inc.; Regeneron Pharmaceuticals, Inc.; and Santen Pharmaceutical Co. Diana V. Do, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Genentech, Inc and Santen Pharmaceutical Co. Grant/Research Support: Genentech, Inc; Regeneron Pharmaceuticals, Inc.; and Santen Pharmaceutical Co. Quan Dong Nguyen, MD, Msc has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: AbbVie; Daichii; Genentech, Inc and Santen Pharmaceutical Co. . Grant/Research Support: Genentech, Inc; Novartis Pharmaceuticals; Opthotech Corporation; Plsvida; Regeneron Pharmaceuticals, Inc.; and Santen Pharmaceutical Co. Editorial Support Disclosure Fabiana Queiroga Silva, Peer Reviewer; Sue Silva, Avlis International, Inc.; and Cheryl Cavanaugh, MS, Evolve Medical Education LLC have no real or apparent conflicts of interest to report.
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!